TEVA
Teva Pharmaceutical Industries Limited
TEVA's outlook is improving, though it still trails on the overall score.
UNH
UnitedHealth Group Incorporated
UNH has the edge over TEVA overall, supported by stronger modeled upside and stronger valuation.
TEVA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Weak |
TEVA's cash flow is currently healthy, and its revenue and profitability are stable, but its balance sheet is weak.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
TEVA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 14x | $6.18 | -86% |
| Forward | 15x | $43.65 | — |
| Fair | 26x | $11.34 | -74% |
| Expensive | 59x | $25.80 | -41% |
| Current | 99x | $43.65 | — |
Historical ranges are pointers, not guarantees.
TEVA's PE is in its expensive range at 99x. If earnings grow as analysts expect, today's price would be 15x next year's earnings, in its cheap range.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH has the edge over TEVA in the historical PE scenario, which offers more potential upside but is not a forecast.
TEVA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect TEVA's earnings to grow and its profitability to improve, with its revenue holding steady.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
TEVA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.82 | +542% |
| Q3 2026 | $0.44 | -27% |
| Q2 2026 | $0.61 | +$0.77 |
| Q1 2026 | $1.34 | +$2.49 |
| Q4 2025 | $1.21 | +$2.66 |
| Q3 2025 | $0.60 | +$1.44 |
| Q2 2025 | -$0.16 | +$0.22 |
| Q1 2025 | -$1.15 | -$0.75 |
| Q4 2024 | -$1.45 | -$0.99 |
TEVA has the edge over UNH on earnings, with more consistent year-over-year improvement.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
TEVA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4.4B | -1.9% |
| Q2 2026 | $4.1B | -0.8% |
| Q1 2026 | $4B | +2.3% |
| Q4 2025 | $1.5B | -65% |
| Q3 2025 | $4.5B | +3.4% |
| Q2 2025 | $4.2B | +0.3% |
| Q1 2025 | $3.9B | +1.9% |
| Q4 2024 | $4.2B | -5.1% |
TEVA's revenue is shrinking: $4.4B last quarter, down 1.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 16% | -3.4 points |
| Q2 2026 | -5.6% | -17 points |
| Q1 2026 | 16% | +3 points |
| Q4 2025 | 20% | +21 points |
| Q3 2025 | 20% | +21 points |
| Q2 2025 | 11% | +11 points |
| Q1 2025 | 13% | +19 points |
| Q4 2024 | -0.7% | -17 points |
TEVA has the edge over UNH on profitability, with a higher operating margin.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over TEVA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
TEVA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $121M | -48% |
| Q2 2026 | $307M | +134% |
| Q1 2026 | -$208M | +$24M |
| Q4 2025 | $1B | +128% |
| Q3 2025 | $233M | -57% |
| Q2 2025 | $131M | +2083% |
| Q1 2025 | -$232M | +$16M |
| Q4 2024 | $446M | -58% |
TEVA generated $1.2B in free cash flow over the past year, up 114% from the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
TEVA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.5% | +18M shares |
| 1 year | +1.6% | +19M shares |
| 3 years | +4.2% | +48M shares |
| 5 years | +6.7% | +74M shares |
| Available history | +8.4% | +92M shares |
TEVA has 1.2B diluted shares, up 1.6% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over TEVA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
TEVA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.9x | High |
| Q2 2026 | 6.8x | High |
| Q1 2026 | 4.7x | High |
| Q4 2025 | 4.8x | High |
| Q3 2025 | 5.2x | High |
| Q2 2025 | 8.1x | High |
| Q1 2025 | 10.5x | High |
| Q4 2024 | 21.6x | High |
TEVA's net debt is about 6.9 years of its operating earnings (EBITDA), up from 5.2 years a year ago.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH has the edge over TEVA on leverage, with a lower net debt burden relative to earnings.
TEVA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 70.1 | Overbought |
| Stochastic | 93.7 | Overbought |
TEVA's weekly RSI is 70 (overbought) and its Stochastic is 94 (overbought).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
TEVA PE vs Healthcare Sector
| Metric | TEVA | Sector median | Relative |
|---|---|---|---|
| PE | 99x | 26x | 284% above |
| PE % | 100 | 29 | 71 pts above |
TEVA is trading at 99x earnings, a 284% premium to the Healthcare sector's median of 26x.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH has the edge over TEVA on valuation relative to its sector.
TEVA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $41.1 | 6.1% above |
| 20 week MA | $37.6 | 16% above |
| 50 week MA | $34.4 | 27% above |
| 100 week MA | $26.3 | 66% above |
| 200 week MA | $19.4 | 125% above |
TEVA has the edge over UNH on trend strength, trading above more of its moving averages.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 9.3% below its 200-week average.
TEVA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.96 | $9.83 | -1.3% |
| 2021 | $9.83 | $8.46 | -14% |
| 2022 | $8.46 | $9.24 | +9.2% |
| 2023 | $9.24 | $10.4 | +13% |
| 2024 | $10.4 | $22.8 | +118% |
| 2025 | $22.8 | $31.9 | +40% |
| 2026 YTD | $31.9 | $43.7 | +37% |
TEVA has the edge over UNH on returns for 2026, with the stronger performance.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has finished three years in a row lower, and it's up 22% so far in 2026.